% | $
Quotes you view appear here for quick access.

Pacific Biosciences of California, Inc. Message Board

sh3ngrace 7 posts  |  Last Activity: Apr 11, 2016 2:08 PM Member since: Apr 22, 2012
  • Reply to


    by oxyieo Apr 11, 2016 10:36 AM
    sh3ngrace sh3ngrace Apr 11, 2016 2:08 PM Flag

    It is legal to exercise options at any time as long as you do not sell the stocks during the dark period.

    Sentiment: Strong Buy

  • [LS18] Luncheon Seminar 18, April 07, 2016, 11:30 - 12:30
    Transforming the State of Genomic Biomarker Discovery and Diagnostic Testing with High-throughput Long-read DNA Sequencing Technologies.

    [Chair] William LaRochelle(Roche Sequencing Solutions)
    [Speaker] Robert Sebra: Assistant Professor, Department of Genetics and Genomic Science, Icahn School of Medicine at Mount Sinai, New York, NY

    Abstract: "Recent advances in the Pacific Biosciences SMRT technology have dramatically increased the sequencing throughput, making it possible for the first time to tackle large-scale population-based studies using long-read sequencing. Beyond the more general, we have developed high-grade clinical assays for routine genetic testing in complex gene regions associated with disease, including long-range, high fidelity sequence capture in tandem with long-read sequencing in BRCA1/2 genes for assessing heritable cancer risk, CYP2D6 for more comprehensive assessment of response to a wide range of drugs including tamoxifen, and the HLA region to more comprehensively characterize variation in HLA genes in support of our novel vaccine development strategies for immunotherapy in different cancers currently in clinical trials."

    Sounds good to me.

    Sentiment: Strong Buy

  • sh3ngrace by sh3ngrace Mar 6, 2016 1:35 AM Flag

    I wonder why Yahoo finance is not updating the insider purchase as yet. On 1/22/2016, Dr. Lucy Shapiro, an Independent Non-Executive Director at PACB purchased 101,666 shares for a total of $338,796. I assume this is an exercise of her stock options. This indicates the corporate insider sentiment is positive on the stock.

    Sentiment: Strong Buy

  • Reply to

    Analysts Ratings

    by sh3ngrace Feb 24, 2016 12:48 AM
    sh3ngrace sh3ngrace Feb 26, 2016 6:15 PM Flag

    Yahoo message board does not allow the link. You can search the following "Pacific Biosciences of California (PACB) Short Interest Up 11.1% in January" and that should give you several link to the different source of financial market news.

    Sentiment: Strong Buy

  • sh3ngrace by sh3ngrace Feb 24, 2016 12:48 AM Flag

    A number of research firms have changed their ratings and price targets for PACB:
    • 2/5/2016 – PACB had its “buy” rating reaffirmed by analysts at Stephens.
    • 2/4/2016 – PACB was downgraded by analysts at Piper Jaffray from an “overweight” rating to a “neutral” rating. They now have a $11.00 price target on the stock, up previously from $9.00.
    • 2/4/2016 – PACB had its price target raised by analysts at JPMorgan Chase & Co. from $10.00 to $12.00.
    • 2/3/2016 – PACB had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $18.00 price target on the stock.
    • 1/4/2016 – PACB had its price target raised by analysts at Cantor Fitzgerald from $11.00 to $18.00. They now have a “buy” rating on the stock.
    • 10/27/15 – PACB was upgraded by analysts at Zacks rating from “hold” to a “buy” rating.

    Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $10.44.

    The shorts should be worried when more good news are coming out in the next few months on the software upgrades, new chemistry, chips fabrication, etc.

    Sentiment: Strong Buy

  • "Quantitative Systematic Strategies purchased a new stake in shares of Pacific Biosciences of California (NASDAQ:PACB) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 77,048 shares of the company’s stock, valued at approximately $1,010,000. Quantitative Systematic Strategies owned about 0.10% of Pacific Biosciences of California at the end of the most recent quarter." - From thevistavoice org.

    The average price is around $13.1/share if we simply divide the amounts by the number of shares. This is a good sign to me and I bet they will continue to acquire more shares with the current low share price.

    Also in yesterday's SC 13 G/A filing, Maverick Capital, Ltd. increased their holding from 6,459,784 in Q4/14 to 7,561,268 in Q4/15, an increase of more than 1 million shares. This is showing how strong on the confidence of Maverick Capital has on PACB's future growth.

    Sentiment: Strong Buy

  • sh3ngrace by sh3ngrace Feb 11, 2016 11:25 AM Flag

    AGBT workshop: Revealing the Unknowns in Medical Research with Long-Read SMRT® Sequencing

    Join PacBio & Roche for our workshop featuring scientists sharing new insights into complex single genes, complete genomes, and rapidly evolving viruses using SMRT Sequencing. Speakers will also discuss their visions for the eventual use of the technology for precision medicine.

    Neil Gunn, President, Roche Sequencing
    Michael Hunkapiller, President and Chief Executive Officer, PacBio

    Friday, February 12th

    This workshop should be a very interesting one.

    Sentiment: Strong Buy

9.65-0.67(-6.49%)Apr 29 4:00 PMEDT